Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 2199170 | [Clinical use of naproxen sodium in muscular skeletal disorders]. | 1990 Mar | Naproxen sodium is a new non-steroid antiinflammatory drug. This paper reported the results of clinical trial of the drug in 229 cases of orthopedic conditions. Among them, 103 cases were observed with double method. The rate of symptomatic relief was 81.3% (75 cases) for rheumatoid arthritis, 72.4% (29 cases) for osteoarthritis, 76.5% (34 cases) for herniations of lumbar discs and 93% (91 cases) for mild post-operative pain. The overall efficacy of the drug was 84.2% with 6.1% side effects, chiefly gastric reactions. | |
| 2475394 | [Therapeutic plasmapheresis using a cell separator]. | 1989 | For the purpose of improving disturbances of the immunosystem 188 plasmaphereses were carried out in 64 patients. This reports deals with the results of 85 therapeutic plasmaphereses in 39 patients with rheumatoid arthritis, diabetes mellitus, and neurodermatitis or pregnant women with rhesus antibodies for diminishing antibody titres. The Soviet equipment of the type RK-0.5, PF-0.5 and FK-3.5 as well as the US devices Aminco and IBM were used. A decrease of the serum protein content from 9-13% appeared immediately after plasmaphereses with 1.3 l of plasma withdrawal per week and an average substitution of 40% of the protein loss by using a 5% solution of albumin. A continual control of this parameter is necessary. | |
| 3296126 | Advances in the physicochemical, immunologic and cytologic investigation of the synovial f | 1987 Jan | Investigations of the pathologic synovial fluid (SF), carried out by numerous research teams, have attempted to elucidate certain pathogenic mechanisms suggestive for diagnosis and treatment. Recent studies have tried to draw some biorheologic patterns of the SF, useful for diagnosis and for the evaluation of certain therapies (synoviorthesis). A systematization of the microcrystalline arthropathies has been possible by microscopic examinations of the SF. Enzymologic studies have demonstrated the properties of enzymatic inhibitors of some classical antirheumatic drugs, suggesting the introduction of new antienzymatic products, and have supported the indication for synoviorthesis. Studies of the SF oligoelements have established new criteria for differential diagnosis, have suggested new treatments (by zinc compounds) and have offered explanations for the good effects of some drugs, such as D-penicillamine. Knowing the role of the toxic oxygen radicals in the pathogeny of the rheumatoid synovial inflammation, drugs with a protective action against the effects of free radicals have been introduced in the antirheumatic therapy. Analyses of the various SF cellular populations, including complex immunologic, cytoenzymatic, optic and ultrastructural cytologic investigations, are opening new prospects of clinical application. The general review of the above-mentioned problems is based on the personal experience of the authors and on the latest data in the specialty literature. | |
| 3024323 | Bolus intramuscular methylprednisolone acetate as a therapeutic adjunct in rheumatoid arth | 1986 Dec | Eighty adult patients with classical or definite rheumatoid arthritis were given 200 bolus injections of intramuscular methylprednisolone acetate (MPA) over four years. This was used strictly as a therapeutic adjunct for polyarticular flares (greater than or equal to 5 swollen joints), not as a singular form of long-term treatment. Good clinical responses, lasting an average of eight weeks, were obtained in the vast majority of patients. Severe toxicity was minimal. Postbolus responses to intravenous ACTH stimulation were measured in 12 patients. We believe that intramuscular bolus injections, used cautiously in carefully selected patients with rheumatoid arthritis, are relatively useful, convenient, inexpensive, and safe. | |
| 2547364 | Extracellular appearance of calpain and calpastatin in the synovial fluid of the knee join | 1989 Jul 31 | Extracellular location of calpain and calpastatin was demonstrated in the cell-free synovial fluid obtained from the knee joint of healthy adult humans and several patients with rheumatoid arthritis. Calpains I and II and a few molecular species of calpastatin were identified by chromatographies on DEAE-cellulose and on Ultrogel AcA 34 columns as well as by immunoelectrophoretic blot analysis. Calpains I and II in the synovial fluid of the patients increased 6.7 times and 3.5 times, respectively, compared with those of the control subjects. With the patients, shortening of the heavy subunits of calpains was noted. Calpastatin also increased in the patients, but it showed rather extensive fragmentation. | |
| 2939913 | European League against Rheumatism study of adverse reactions to D-penicillamine. | 1986 May | An international multicentre study of adverse reactions to D-penicillamine was undertaken on 2879 patients exposed to the drug--1491 of them a prospective sample. The majority of patients were being treated for rheumatoid arthritis. Over a period of 18 months, 319 (21%) of patients in the prospective sample developed adverse reactions necessitating drug withdrawal; two thirds of these occurred during the first 3 months of treatment. The most frequently-occurring adverse reactions involved skin (6%), kidneys (4%), gastro-intestinal tract (4%) and haemopoiesis (3%). Adverse effects, considered to be serious by the reporting physician, included fever and leucopenia during the early weeks of treatment and, after some months of drug exposure, proteinuria, myasthenia gravis, dyspnoea and pemphigus. Two patients died, one of fulminating septicaemia and the other was found at autopsy to have had multiple lung abscesses following unexplained anaemia and hemiparesis. | |
| 3409641 | Vasculitis in Reiter's syndrome. | 1988 Mar | A patient is described with both Reiter's syndrome and cutaneous vasculitis characterised by livedo reticularis. The development of the Reiter's syndrome immediately preceded the onset of vasculitis. It is suggested that Reiter's syndrome is a previously unrecognised potential cause of vasculitis in which infection may initiate the vasculitic reaction. | |
| 3675660 | Serum concentrations of salicylate and naproxen during concurrent therapy in patients with | 1987 Oct | The kinetic interaction between salicylate and naproxen was investigated in 25 rheumatoid arthritis patients. Kinetic interactions were tested in serum after patients had been on each drug regimen for 1 month. Salicylate decreased serum naproxen concentration from 89.5 mg/liter to 65.9 mg/liter (P less than 0.001) and increased serum naproxen clearance by 56%. Naproxen had minimal effect on serum salicylate concentrations. | |
| 2166487 | Monocyte activation in early onset rheumatoid arthritis. | 1990 Jul | Monocytes from peripheral blood and synovial fluid of patients with definite and classic rheumatoid arthritis spontaneously produced significantly greater amounts of prostaglandin E2 (PGE2), leukotriene B4 (LTB4), and interleukin-1 beta (IL-1 beta) than samples of peripheral blood from normal controls. Peripheral blood monocytes from patients with rheumatoid arthritis produced significantly greater amounts of PGE2 than control samples when stimulated with lipopolysaccharide. There were no significant differences in the spontaneous release of superoxide or N-acetyl-beta-D-glucosaminidase by peripheral blood monocytes between patients and healthy controls. Both stimulated and unstimulated peripheral blood monocytes from patients with definite or classic rheumatoid arthritis produced significantly greater amounts of PGE2 than samples from normal controls. This was true, regardless of the stage of disease and the presence or absence of roentgenological joint abnormalities. Amounts of N-acetyl-beta-D-glucosaminidase released by peripheral blood monocytes from patients correlated positively with the erythrocyte sedimentation rate (ESR) and negatively with duration of disease. Amounts of IL-1 beta and N-acetyl-beta-D-glucosaminidase released from the peripheral blood monocytes of patients who had had their disease for less than one year were significantly higher than those of normal controls. There were no significant correlations between the types of treatment and the amounts of PGE2, LTB4, IL-1 beta or N-acetyl-beta-D-glucosaminidase released by peripheral blood monocytes in patients with rheumatoid arthritis. The findings suggest that monocytes are activated in patients with rheumatoid arthritis both at the onset of disease and during its chronic phase, and that they produce large amounts of mediators which may have a role in the induction and extension of the inflammatory process which leads to tissue damage. | |
| 2031660 | IgA-containing immune complexes in the circulation of patients with primary Sjögren's syn | 1991 Feb | IgA-, IgM- and IgG-containing immune complexes (CIC) were detected in 48, 19 and 12% of 52 patients with primary Sjögren's syndrome (SS), in 36, 38 and 56% of 45 patients with rheumatoid arthritis, and in 8, 5 and 3% of 40 normal controls. A high proportion of primary SS patients also had considerable amounts of serum IgA and elevated levels of IgA with rheumatoid factor (RF) activity. IgA-CIC and IgA-RF were more frequent (P less than 0.03 and less than 0.001) in the 27 primary SS patients with, than in the 25 without extraglandular manifestations. IgA-CIC could play a role in mediating the tissue injury associated with primary SS. | |
| 3696743 | Development of a questionnaire for the assessment of active and passive coping strategies | 1987 Oct | This study describes the development of a self-report questionnaire, the Vanderbilt Pain Management Inventory, which assesses the frequency with which chronic pain patients use active or passive coping strategies when their pain reaches a moderate or greater level of intensity. Two internally reliable scales, Active Coping and Passive Coping, were derived using factor analytic techniques from a sample of 361 rheumatoid arthritis patients. The 2 scales showed an opposite pattern of relationships with criterion measures. While Active Coping was associated with reports of less pain, less depression, less functional impairment, and higher general self-efficacy, Passive Coping was correlated with reports of greater depression, greater pain and flare-up activity, greater functional impairment, and lower general self-efficacy. The relationship of these scales to previous theory and research on coping is presented. These scales appear useful for the assessment of coping strategies in clinical settings and in treatment outcome research on chronic pain. | |
| 3492746 | Relationship between serum ferritin, iron stores and disease activity in rheumatoid arthri | 1986 Jul | Bone marrow aspirate from the sternum of 40 patients with active or inactive rheumatoid arthritis (RA) was stained with Perls' Prussian blue for iron determination. In these patients serum ferritin concentrations were correlated with other indices of iron stores and disease activity. In patients with active RA and without bone marrow iron stores, serum ferritin was significantly lower than in patients with either active or inactive RA and iron stores. In patients with bone marrow iron stores, serum ferritin was directly correlated with erythrocyte sedimentation rate (ESR), Ritchie index, alpha 1-antitrypsin, alpha 1-acid glycoprotein and desferrioxamine (DFO)-induced sideruria, while an inverse correlation of serum ferritin with hemoglobin and serum iron was observed. In all patients serum ferritin was significantly correlated only with DFO-induced sideruria and unsaturated iron-binding capacity (UIBC). Thus, serum ferritin is an index of iron stores also in rheumatoid arthritis. In active disease, higher than expected values of serum ferritin are probably due to a shifting of iron from the circulating pool to the reticuloendothelial cells of the synovial membrane. | |
| 3619960 | Anticardiolipin antibodies in patients with rheumatic diseases. | 1987 Jul | Recent attention has focused on the presence of anticardiolipin (ACL) antibodies and their possible role in recurrent thrombosis and abortions in patients with systemic lupus erythematosus. We analyzed ACL antibodies in 243 consecutive patients to determine their frequency in patients with different rheumatic disorders. A significantly elevated frequency was found in patients with systemic lupus erythematosus (38%), rheumatoid arthritis (33%), and psoriatic arthritis (28%). No correlation could be found between ACL antibody levels and recurrent thrombosis. In patients with rheumatoid arthritis there was a significant correlation between ACL antibodies and a history of repeated abortions. No significant association was found between ACL antibodies and other autoantibodies except in patients with rheumatoid arthritis; ACL antibody-positive rheumatoid arthritis patients were much more likely to be antinuclear antibody-positive (P less than 0.0002). | |
| 3823910 | Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotr | 1987 Feb | Methotrexate therapy has been effective in the treatment of RA with short term experience suggesting little serious adverse reactions. Our review of 168 patients receiving methotrexate has identified nine patients with probable or possible methotrexate-induced pulmonary toxicity, giving a prevalence of 5% and an incidence of 3.9 per 100 patients per year. No clinical or laboratory features showed an association that could potentially predict the development of pulmonary disease. All patients experienced complete recovery with supportive care and/or corticosteroid therapy. Clinical monitoring for this complication is warranted in all patients receiving long term methotrexate therapy for RA. | |
| 2846219 | Connective tissue metabolites in serum as markers of disease activity in patients with rhe | 1988 Apr | The serum levels of aminoterminal type III procollagen peptide (S-PIIINP), immunoreactive prolyl 4-hydroxylase protein (S-IRPH), 7S domain of collagen type IV (S-Col IV, 7S), and fragment P1 of laminin (S-Lam), which are associated with the metabolism of extracellular interstitial collagens and basement membranes, were measured sequentially for two years in 14 rheumatoid arthritis (RA) patients undergoing disease modifying antirheumatic drug treatment. Elevated S-PIIINP, S-IRPH, and S-Col IV, 7S levels were demonstrated in active RA. In active disease the metabolites showed some correlation with clinical and serological signs of disease activity. A high average synovial fluid/serum concentration ratio of PIIINP and of Col IV, 7S supports the concept that the increased serum levels of PIIINP and Col IV, 7S originated from the diseased joints. After 2 years of treatment a decline was observed in S-PIIINP and S-Col IV, 7S in treatment responders. However, the median levels of S-PIIINP and S-IRPH were still above the upper limit of normal, suggesting smouldering, subclinical inflammatory processes. S-Lam remained within the normal range in active and inactive disease. | |
| 2727474 | A comparison of estimated proportional hazards models and regression trees. | 1989 May | We present examples of the usage of regression trees for censored response via two real world datasets, one a rheumatoid arthritis survival study and the other a hip replacement study, and draw comparisons with the results of Cox proportional hazards modelling. The two methods pursue different goals. Motivation of the tree techniques is the desire to extract meaningful prognostic groups while the proportional hazards model enables assessment of the impact of risk factors. The methods are thus complementary. For the arthritis study the two techniques corroborate one another, although the flavour of the conclusions derived differ. For the hip replacement study, however, the regression tree approach reveals structure that would not emerge from a routine proportional hazards analysis. We also discuss the treatment of data analytic issues such as the handling of missing values and influence in the presence of non-uniform censoring. | |
| 3092712 | Auranofin or D-penicillamine in the treatment of rheumatoid arthritis. | 1986 Oct | Ninety patients were entered into a randomized, controlled, double-blind trial lasting 12 months to compare auranofin (6 mg/d), and D-penicillamine (250 mg/d for 4 weeks, 500 mg/d for 4 weeks, then 750 mg/d thereafter) in the treatment of rheumatoid arthritis. Most patients in both groups completed the trial with significant improvement in all quantitative measures of efficacy. Patients treated with D-penicillamine were more likely to have "important improvement" in physician global assessment, swollen joint count, and score and grip strength. The overall frequency of side effects was similar between the two groups; however, more patients were withdrawn for adverse effects from the D-penicillamine group, and proteinuria (greater than or equal to 2+) and thrombocytopenia (less than 100 000 mm3) occurred significantly more frequently with D-penicillamine than auranofin (p = 0.028). These results suggest that in the dosage regimen used, auranofin is safer than D-penicillamine but that D-penicillamine tends to show greater clinical effectiveness in patients with rheumatoid arthritis. | |
| 3955811 | Effect of phytohemagglutinin on concentrations of glucocorticoid receptors in lymphocytes | 1986 Apr | We examined the effect of phytohemagglutinin (PHA) on glucocorticoid receptors in lymphocytes, using peripheral mononuclear leukocytes from patients with connective tissue diseases. Glucocorticoid receptor concentrations and dissociation constants (Kd) for [3H]dexamethasone binding to lymphocytes from patients with rheumatoid arthritis, Sjögren's syndrome, and other connective tissue diseases did not differ significantly from values for normal volunteers. Kd values correlated positively with glucocorticoid receptor concentrations after PHA stimulation both in normal volunteers and in patients with connective tissue diseases. The correlations (r values) for the control group and patients were not significantly different. | |
| 2547060 | Antiperinuclear factor, a rheumatoid arthritis specific autoantibody: its relation to Epst | 1989 May | We studied the prevalence of antiperinuclear factor (APF), an antibody frequently (50-80%) present in sera of patients with rheumatoid arthritis (RA), in different groups of patients. Sera from 123 patients with RA and 28 patients with recent Epstein-Barr virus (EBV) infection showed APF in 63 and 51% of the patients, respectively. These frequencies were significantly increased (p0.001) when compared with 123 healthy blood donors (12%) and in 58 patients with herpes virus infections other than EBV (18%). Relations with other EBV elicited antibodies in RA and the relevance of EBV in RA are discussed. Our data suggest that EBV might be the immunogen for APF, an antibody, until now considered to be an autoantibody. | |
| 1916875 | [Macrophage activity during high dose steroid pulse therapy and 7S-immunoglobulin administ | 1991 Jun | Patients with connective tissue diseases show increased neopterin levels indicating the activation of the monocyte system. Corticosteroids reduce the release of neopterin in vivo and in vitro. After i.v. 7S-Ig administration neopterin increases in vivo transiently and decreases beyond the pretherapeutic levels. Addition of 7S-Ig to cell cultures reduces the macrophage activation. |